Rallybio: Funding, Investors & Team (Sep 2026)
Rallybio is a biotechnology company focused on discovering and fast-tracking the development of innovative treatments for severe and rare diseases. Since its establishment in January 2018, Rallybio has assembled a collection of promising potential therapies that are currently being developed to treat rare conditions in the fields of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The company is led by a team of seasoned biopharmaceutical industry professionals with a wealth of knowledge in research, development, and rare disease management.
Rallybio has raised $152M across 2 funding rounds on record, the most recent an undisclosed round of $6.6M announced in Apr 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Rallybio Company Profile and Key Stats
Latest funding round on record: Apr 2024.
Rallybio Funding Rounds
Rallybio raised $145M in an undisclosed round announced in Apr 2020.
4 years later, an undisclosed round of $6.6M was announced in Apr 2024.
Rallybio Founders and Leadership Team
Contact details for the Rallybio team: 2 of 2 have an email address on file.
Start 14-day free trial →Rallybio Funding Compared to Other Biotechnology Startups
Rallybio's latest round of $6.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Rallybio in Biotechnology and Farmington
Companies Similar to Rallybio
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Rallybio Funding FAQs
What does Rallybio do?
Rallybio is a biotechnology company focused on discovering and fast-tracking the development of innovative treatments for severe and rare diseases. Since its establishment in January 2018, Rallybio has assembled a collection of promising potential therapies that are currently being developed to treat rare conditions in the fields of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The company is led by a team of seasoned biopharmaceutical industry professionals with a wealth of knowledge in research, development, and rare disease management.
How much funding has Rallybio raised?
Rallybio has raised $152M across 2 rounds on record. The most recent is an undisclosed round of $6.6M announced in Apr 2024.
When did Rallybio last raise funding?
Rallybio's most recent funding round on record is an undisclosed round of $6.6M, announced in Apr 2024.
Who founded Rallybio?
FundedIQ lists Stephen Uden (Founder) at Rallybio.
Who is the CEO of Rallybio?
Joe Dillon is listed as CEO at Rallybio.
Where is Rallybio headquartered?
Rallybio is based in Farmington, Connecticut, United States.
How many employees does Rallybio have?
Rallybio is in the 11-50 employee band.
How does Rallybio's funding compare to other Biotechnology startups?
Rallybio's latest round of $6.6M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Rallybio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Rallybio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.